{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:12:19Z","timestamp":1776309139674,"version":"3.50.1"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0236264","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T18:32:57Z","timestamp":1596565977000},"page":"e0236264","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Outcomes and adverse events of pre- and extensively drug-resistant tuberculosis patients in Kinshasa, Democratique Republic of the Congo: A retrospective cohort study"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3983-1533","authenticated-orcid":true,"given":"Innocent Murhula","family":"Kashongwe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fina","family":"Mawete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leopoldine","family":"Mbulula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don Jean","family":"Nsuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Losenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Anshambi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murielle","family":"Aloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Kaswa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Marie Ntumba","family":"Kayembe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Umba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois Bompeka","family":"Lepira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zacharie Munogolo","family":"Kashongwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"key":"pone.0236264.ref001","unstructured":"Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"pone.0236264.ref002","doi-asserted-by":"crossref","DOI":"10.30875\/52320670-en","volume-title":"WHO progress report 2011","author":"World Health Organization","year":"2011"},{"key":"pone.0236264.ref003","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1183\/09031936.00162314","article-title":"Novel drugs against tuberculosis: a clinician's perspective","volume":"45","author":"ID Olaru","year":"2015","journal-title":"Eur Respir J"},{"key":"pone.0236264.ref004","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/S0140-6736(10)60410-2","article-title":"Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis","volume":"375","author":"NR Gandhi","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"pone.0236264.ref005","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Bothamley GH and al. Treatment of Drug-Resistant Tuberculosis. An Official ATS\/CDC\/ERS\/IDSA Clinical Practice Guideline","volume":"200","author":"P Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"pone.0236264.ref006","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.5588\/ijtld.17.0468","article-title":"The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?","volume":"21","author":"A Reuter","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0236264.ref007","first-page":"PA1903","article-title":"The global response to rifampicin-resistant tuberculosis: current situation and recent trends","volume":"48","author":"D Falzon","year":"2016","journal-title":"Eur Respir J"},{"key":"pone.0236264.ref008","unstructured":"World Health Organization (2016) Global Tuberculosis Report 2016. WHO, Geneva. http:\/\/www.who.int\/tb\/publications\/global_report\/en\/"},{"key":"pone.0236264.ref009","unstructured":"National Tuberculosis Program of DR Congo. Rapport du Groupe Th\u00e9matique sur la Tuberculose Pharmacor\u00e9sistante Pour la Revue Externe \u00e0 Mi-Parcours. PNLT RD Congo, 2016."},{"key":"pone.0236264.ref010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4236\/jtr.2018.62012","article-title":"First use of bedaquiline in democratic republic of Congo: two case series of pre extensively drug resistant tuberculosis","volume":"6","author":"MI Kashongwe","year":"2018","journal-title":"J Tuberc Res"},{"key":"pone.0236264.ref011","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1183\/09031936.00136312","article-title":"Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis","volume":"42","author":"GB Migliori","year":"2013","journal-title":"Eur Respir J"},{"key":"pone.0236264.ref012","volume-title":"Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis","author":"J Caminero","year":"2013"},{"key":"pone.0236264.ref013","volume-title":"The use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. WHO\/HTM\/TB\/2013.6","author":"World Health Organization","year":"2013"},{"issue":"1","key":"pone.0236264.ref014","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1574891X12666170619101904","article-title":"Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens","volume":"13","author":"N Riccardi","year":"2018","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"pone.0236264.ref015","volume-title":"The use of Delamanid in the Treatment of Multidrug Tuberculosis: Interim Policy Guidance. WHO\/HTM\/TB\/2014.23","author":"World Health Organization","year":"2014"},{"key":"pone.0236264.ref016","doi-asserted-by":"crossref","first-page":"407","DOI":"10.5588\/ijtld.17.0706","article-title":"Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis","volume":"22","author":"V Cox","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0236264.ref017","doi-asserted-by":"crossref","first-page":"1700387","DOI":"10.1183\/13993003.00387-2017","article-title":"Centis R and al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","volume":"49","author":"SE Borisov","year":"2017","journal-title":"Eur Respir J"},{"issue":"1","key":"pone.0236264.ref018","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12879-019-4211-0","article-title":"for StopTB Italia Onlus Group. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres","volume":"19","author":"N Riccardi","year":"2019","journal-title":"BMC Infect Dis"},{"key":"pone.0236264.ref019","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1183\/09031936.00145014","article-title":"Linezolid to treat MDR-\/XDR-tuberculosis: available evidence and future scenarios","volume":"45","author":"G Sotgiu","year":"2015","journal-title":"Eur Respir J"},{"key":"pone.0236264.ref020","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","article-title":"Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study","volume":"6","author":"K Schnippel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"pone.0236264.ref021","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1183\/09031936.00035114","article-title":"Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China","volume":"45","author":"S Tang","year":"2015","journal-title":"Eur Respir J"},{"key":"pone.0236264.ref022","volume-title":"WHO Treatment Guidelines for Multidrug and Rifampicin- Resistant Tuberculosis, 2018 Update","author":"World Health Organization","year":"2018"},{"key":"pone.0236264.ref023","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5588\/ijtld.17.0660","article-title":"Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs","volume":"22","author":"A van Deun","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0236264.ref024","doi-asserted-by":"crossref","first-page":"1701354","DOI":"10.1183\/13993003.01354-2017","article-title":"A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis","volume":"50","author":"P Miotto","year":"2017","journal-title":"Eur Respir J"},{"key":"pone.0236264.ref025","first-page":"5","article-title":"Use of bedaquiline as a replacement for aminoglycosides in the MDR-TB regimen and the risk of acquired resistance: a case report","volume":"1","author":"IM Kashongwe","year":"2019","journal-title":"J Pulm Med Respir Care"},{"key":"pone.0236264.ref026","unstructured":"Agence Publique Francaise de Recherches sur le Sida et les Hepatitis Virales. Echelle ANRS de Cotation de la Gravit\u00e9 des \u00c9v\u00e9nements Ind\u00e9siirables Chez L\u2019adulte. Version 6, 9 Septembre 2003. Paris, France, ANRS, 2003."},{"key":"pone.0236264.ref027","volume-title":"Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis","author":"World Health Organization","year":"2006"},{"key":"pone.0236264.ref028","volume-title":"WHO Handbook for Guideline Development, Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, WHO\/HTM\/TB\/2014.11","author":"World Health Organization","year":"2014"},{"key":"pone.0236264.ref029","volume-title":"WHO Treatment Guidelines for Drug-Resistant Tuberculosis 2016 Update, WHO\/HTM\/TB\/2016.04","author":"World Health Organization","year":"2016"},{"key":"pone.0236264.ref030","volume-title":"Rapid Communication: Key Changes to Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis (MDR\/RR-TB). Licence: CC BY-NC-SA 3.0 IGO","author":"World Health Organization","year":"2018"},{"key":"pone.0236264.ref031","volume-title":"WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Licence: CC BY-NC-SA 3.0IGO","author":"World Health Organization","year":"2019"},{"key":"pone.0236264.ref032","doi-asserted-by":"crossref","first-page":"979","DOI":"10.5588\/ijtld.14.0944","article-title":"Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis","volume":"19","author":"N Ndjeka","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0236264.ref033","doi-asserted-by":"crossref","first-page":"766","DOI":"10.5588\/ijtld.17.0840","article-title":"Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia","volume":"22","author":"C Hewison","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0236264.ref034","doi-asserted-by":"crossref","first-page":"720","DOI":"10.5588\/ijtld.18.0575","article-title":"Extensively drug-resistant tuberculosis 'hotspots' and sociodemographic associations in Durban, South Africa","volume":"23","author":"ML Peterson","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0236264.ref035","doi-asserted-by":"crossref","first-page":"1801528","DOI":"10.1183\/13993003.01528-2018","article-title":"High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen","volume":"52","author":"N Ndjeka","year":"2018","journal-title":"Eur Respir J"},{"key":"pone.0236264.ref036","first-page":"517","article-title":"Haute efficacit\u00e9 d'un protocole de 12 mois pour les patientsatteints de TB-MR au Cameroun","volume":"19","author":"C Kuaban","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0236264.ref037","doi-asserted-by":"crossref","first-page":"645","DOI":"10.5588\/ijtld.18.0622","article-title":"Management of patients with multidrug-resistant tuberculosis","volume":"23","author":"C Lange","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0236264.ref038","volume-title":"Global Tuberculosis Report 2018. Licence: CC BY-NC-SA 3.0 IG","author":"World Health Organization","year":"2018"},{"key":"pone.0236264.ref039","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.5588\/ijtld.18.0657","article-title":"Tuberculosis and diabetes mellitus: a dose-response relationship between the odds of tuberculosis and HbA1c","volume":"23","author":"K Viney","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0236264.ref040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5588\/pha.17.0098","article-title":"Did diabetes mellitus affect treatment outcome in drug-resistant tuberculosis patients in Pakistan from 2010 to 2014?","volume":"8","author":"A Latif","year":"2018","journal-title":"Public Health Action"},{"key":"pone.0236264.ref041","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.arbres.2015.03.012","article-title":"Primera serie de pacientes con TB-XDR y pre-XDR tratados conesquemas que incluyeron meropenem-clavulanato en Argentina","volume":"51","author":"D Palmero","year":"2015","journal-title":"Arch Bronconeumol"},{"key":"pone.0236264.ref042","unstructured":"World Health Organization. Global Tuberculosis Report 2017. World Health Organization. License: CC BY-NC-SA 3.0 IGO. https:\/\/apps.who.int\/iris\/handle\/10665\/259366."},{"key":"pone.0236264.ref043","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Nafees Ahmad","year":"2018","journal-title":"Lancet"},{"key":"pone.0236264.ref044","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3201\/eid1703.100919","article-title":"Extensively drug-resistant tuberculosis, China","volume":"17","author":"S Tang","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"pone.0236264.ref045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1086\/653115","article-title":"Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis","volume":"51","author":"KR Jacobson","year":"2010","journal-title":"Clin Infect Dis"},{"key":"pone.0236264.ref046","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of Highly Drug-Resistant Pulmonary Tuberculosis","volume":"382","author":"for the Nix-TB Trial Team","year":"2020","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0236264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T18:33:31Z","timestamp":1596566011000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0236264"}},"subtitle":[],"editor":[{"given":"Helen Suzanne","family":"Cox","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,8,4]]},"references-count":46,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0236264","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,4]]}}}